Literature DB >> 22002658

Amyloid-β associated volume loss occurs only in the presence of phospho-tau.

Rahul S Desikan1, Linda K McEvoy, Wesley K Thompson, Dominic Holland, J Cooper Roddey, Kaj Blennow, Paul S Aisen, James B Brewer, Bradley T Hyman, Anders M Dale.   

Abstract

The relationship between neurodegeneration and the 2 hallmark proteins of Alzheimer's disease, amyloid-β (Aβ) and tau, is still unclear. Here, we examined 286 nondemented participants (107 cognitively normal older adults and 179 memory impaired individuals) who underwent longitudinal magnetic resonance (MR) imaging and lumbar puncture. Using mixed effects models, we investigated the relationship between longitudinal entorhinal cortex atrophy rate, cerebrospinal fluid (CSF) p-tau(181p) and CSF Aβ(1-42) . We found a significant relationship between elevated entorhinal cortex atrophy rate and decreased CSF Aβ(1-42) only with elevated CSF p-tau(181p) . Our findings indicate that Aβ-associated volume loss occurs only in the presence of phospho-tau in humans at risk for dementia.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002658      PMCID: PMC3368003          DOI: 10.1002/ana.22509

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.

Authors:  Ming Jin; Nina Shepardson; Ting Yang; Gang Chen; Dominic Walsh; Dennis J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-18       Impact factor: 11.205

2.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

3.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

Review 4.  Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Authors:  Lars M Ittner; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2010-12-31       Impact factor: 34.870

5.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks.

Authors:  Kishore V Kuchibhotla; Samuel T Goldman; Carli R Lattarulo; Hai-Yan Wu; Bradley T Hyman; Brian J Bacskai
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 10.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

View more
  62 in total

1.  Toward a multifactorial model of Alzheimer disease.

Authors:  Martha Storandt; Denise Head; Anne M Fagan; David M Holtzman; John C Morris
Journal:  Neurobiol Aging       Date:  2012-01-20       Impact factor: 4.673

2.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

3.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.

Authors:  Nikki H Stricker; Hiroko H Dodge; N Maritza Dowling; S Duke Han; Elena A Erosheva; William J Jagust
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

4.  Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.

Authors:  Ming-Jang Chiu; Ya-Fang Chen; Ta-Fu Chen; Shieh-Yueh Yang; Fan-Pei Gloria Yang; Tien-Wen Tseng; Jen-Jie Chieh; Jia-Chun Rare Chen; Kai-Yuan Tzen; Mau-Sun Hua; Herng-Er Horng
Journal:  Hum Brain Mapp       Date:  2013-10-15       Impact factor: 5.038

5.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Authors:  Chenjie Xia; Sara J Makaretz; Christina Caso; Scott McGinnis; Stephen N Gomperts; Jorge Sepulcre; Teresa Gomez-Isla; Bradley T Hyman; Aaron Schultz; Neil Vasdev; Keith A Johnson; Bradford C Dickerson
Journal:  JAMA Neurol       Date:  2017-04-01       Impact factor: 18.302

6.  Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Authors:  R S Desikan; L K McEvoy; D Holland; W K Thompson; J B Brewer; P S Aisen; O A Andreassen; B T Hyman; R A Sperling; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2012-09-13       Impact factor: 3.825

7.  The role of amyloid-β, tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing?

Authors:  M Filippi; E Canu; F Agosta
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-23       Impact factor: 3.825

8.  Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Imaging Med       Date:  2012-06

Review 9.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

Review 10.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.

Authors:  Anders M Fjell; Linda McEvoy; Dominic Holland; Anders M Dale; Kristine B Walhovd
Journal:  Prog Neurobiol       Date:  2014-02-16       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.